Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 41 D014615
SNOMED-CT 64 111852003
UMLS 69 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results_in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted_by contact with the vaccination site before it has healed, or transmitted_by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to cowpox and smallpox, and has symptoms including rash, fever and body aches. An important gene associated with Vaccinia is VRK1 (Vaccinia Related Kinase 1), and among its related pathways/superpathways are Influenza A and RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and t cells, and related phenotype is hematopoietic system.

Wikipedia : 72 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • rash
  • fever
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.32 AZI2 DUSP3 EIF2AK2 EIF2S1 EPS15 IL2

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
2 Antibodies Phase 4,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 2,Phase 1
4 Immunoglobulins Phase 4,Phase 2,Phase 1
5 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
6 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
7
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
9
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 2767 441203 84093
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1 33069-62-4 36314
11
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 60843 446556
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
15
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
16
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
17
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 143 6006
18 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 2, Phase 3,Phase 1
20 Analgesics Phase 3,Phase 2,Phase 1
21 Anticonvulsants Phase 3
22 Neurotropin Phase 3
23 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
24 Iron-Dextran Complex Phase 3,Phase 2
25 Krestin Phase 3,Phase 2,Phase 1
26 Micronutrients Phase 3,Phase 2
27 Nicotinic Acids Phase 3,Phase 2
28 Protein Kinase Inhibitors Phase 3,Phase 2
29 Trace Elements Phase 3,Phase 2
30 Vitamin B Complex Phase 3,Phase 2
31 Vitamins Phase 3,Phase 2
32 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1
33 Antimitotic Agents Phase 2, Phase 3,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
35 Antiviral Agents Phase 2, Phase 3,Phase 1
36 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2
38 Antimetabolites Phase 2, Phase 3,Phase 1
39 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
40 Angiogenesis Modulating Agents Phase 2, Phase 3
41
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
42 Folic Acid Antagonists Phase 2, Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
44 Folate Nutraceutical Phase 3,Phase 2
45 Vitamin B3 Nutraceutical Phase 3,Phase 2
46 Vitamin B9 Nutraceutical Phase 3,Phase 2
47
Metronidazole Approved Phase 2,Phase 1 443-48-1 4173
48
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
49
Goserelin Approved Phase 2 65807-02-5 5311128 47725
50
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 239)

# Name Status NCT ID Phase Drugs
1 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
2 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
3 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
4 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
5 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
6 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
7 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
8 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
9 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
10 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3 Sorafenib
11 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
12 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
13 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
14 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
15 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3 placebo
16 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
17 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
18 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
19 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
20 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
21 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
22 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
23 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
24 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
25 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
26 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
27 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
28 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
29 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
30 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
31 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
32 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
33 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
34 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
35 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
36 A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Completed NCT00998543 Phase 2
37 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
38 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
39 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
40 Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
41 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
42 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
43 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
44 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
45 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
46 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2
47 Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
48 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
49 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
50 Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer Completed NCT00450463 Phase 2 Sargramostim (GM-CSF, Leukine);Flutamide (Eulexin)

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

18
Skin

MalaCards organs/tissues related to Vaccinia:

38
Prostate, T Cells, Skin, Liver, Lung, Monocytes, B Cells

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 1075)
# Title Authors Year
1
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. ( 29259007 )
2018
2
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. ( 29399394 )
2018
3
Labeling and Single-Particle-Tracking-Based Entry Mechanism Study of Vaccinia Virus from the Tiantan Strain. ( 29392930 )
2018
4
Vaccinia Virus in Blood Samples of Humans, Domestic and Wild Mammals in Brazil. ( 29346277 )
2018
5
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
6
In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades. ( 29427676 )
2018
7
Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. ( 29444943 )
2018
8
Genital Autoinoculation with Vaccinia: A Look at Two Cases. ( 29415160 )
2018
9
Ocular Vaccinia Infection in Dairy Worker, Brazil. ( 29260673 )
2018
10
Vaccinia virus in Feces and Urine of Wild Rodents from SALo Paulo State, Brazil. ( 29360742 )
2018
11
High Initial Sputter Rate Found for Vaccinia Virions Using Isotopic Labeling, NanoSIMS, and AFM. ( 29295620 )
2018
12
Lamin A/C augments Th1 differentiation and response against vaccinia virus and Leishmania major. ( 29311549 )
2018
13
A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes. ( 29393023 )
2018
14
Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins. ( 29386289 )
2018
15
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-I94 with a Set of Gene Deletions on Several Viral Pathways. ( 29367944 )
2018
16
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. ( 29339750 )
2018
17
Voluntary Wheel Running Does Not Alter Mortality to or Immunogenicity of Vaccinia Virus in Mice: A Pilot Study. ( 29354074 )
2017
18
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. ( 28880972 )
2017
19
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro. ( 28931212 )
2017
20
Tagging of the vaccinia virus protein F13 with mCherry causes aberrant virion morphogenesis. ( 28933687 )
2017
21
Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. ( 29257056 )
2017
22
Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations. ( 28790404 )
2017
23
Concomitant helminth infection downmodulates the Vaccinia virus-specific immune response and potentiates virus-associated pathology. ( 28003150 )
2017
24
Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA. ( 28727764 )
2017
25
Cellular interactome analysis of vaccinia virus K7 protein identifies three transport machineries as binding partners for K7. ( 28815417 )
2017
26
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. ( 28846477 )
2017
27
Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus. ( 28081672 )
2017
28
Autism-like behavior caused by deletion of vaccinia-related kinase 3 is improved by TrkB stimulation. ( 28899869 )
2017
29
Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. ( 28079473 )
2017
30
Construction & establishment of two minigenome rescue systems for Chandipura virus driven by recombinant vaccinia virus expressing T7 polymerase. ( 28948956 )
2017
31
Preparation of Cell Cultures and Vaccinia Virus Stocks. ( 28060410 )
2017
32
A Model to Detect Autochthonous Group 1 and 2 Brazilian Vaccinia virus Coinfections: Development of a qPCR Tool for Diagnosis and Pathogenesis Studies. ( 29301202 )
2017
33
Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. ( 28785262 )
2017
34
CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice. ( 29281850 )
2017
35
Ecological niche modeling to determine potential niche of Vaccinia virus: a case only study. ( 28784125 )
2017
36
Characterization of a PKR inhibitor from the pathogenic ranavirus, Ambystoma tigrinum virus, using a heterologous vaccinia virus system. ( 28919326 )
2017
37
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma. ( 28808676 )
2017
38
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. ( 28819261 )
2017
39
Corrigendum to "Short communication: Survival of Vaccinia virus in inoculated cheeses during 60-day ripening" (J. Dairy Sci. 100:7051-7054). ( 28923659 )
2017
40
Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice. ( 28813507 )
2017
41
Vaccinia-related kinase 3 (VRK3) sets the circadian period and amplitude by affecting the subcellular localization of clock proteins in mammalian cells. ( 28412365 )
2017
42
Selective recruitment of nucleoporins on vaccinia virus factories and the role of Nup358 in viral infection. ( 28963881 )
2017
43
Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. ( 28046039 )
2017
44
Deletion of the Vaccinia Virus B1 Kinase Reveals Essential Functions of This Enzyme Complemented Partly by the Homologous Cellular Kinase VRK2. ( 28515294 )
2017
45
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. ( 28057259 )
2017
46
Generation of Recombinant Vaccinia Viruses. ( 28060405 )
2017
47
Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells. ( 28951871 )
2017
48
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(Ar)): a global review. ( 28938920 )
2017
49
Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems. ( 28837572 )
2017
50
Vaccinia virus encodes a novel inhibitor of apoptosis that associates with the apoptosome. ( 28904196 )
2017

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 AZI2 BANF1 CYB5R3 EIF2AK2 EIF2S1 EPS15
2 cytosol GO:0005829 9.44 BANF1 DUSP3 EIF2AK2 EIF2S1 EPS15 IRF3

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.89 EIF2AK2 IRF3 IRF7 NLRP1 TBKBP1
2 immune system process GO:0002376 9.88 EIF2AK2 IL2 IRF3 IRF7 NLRP1
3 regulation of cell shape GO:0008360 9.74 VRK1 VRK2 VRK3
4 membrane organization GO:0061024 9.71 EPS15 ITSN1 WASL
5 response to virus GO:0009615 9.7 BANF1 EIF2AK2 IRF7
6 protein autophosphorylation GO:0046777 9.67 EIF2AK2 EIF2S1 VRK1 VRK2
7 vesicle organization GO:0016050 9.56 EPS15 WASL
8 positive regulation of interferon-beta production GO:0032728 9.55 IRF3 IRF7
9 regulation of type I interferon production GO:0032479 9.51 IRF3 IRF7
10 positive regulation of interferon-alpha production GO:0032727 9.46 IRF3 IRF7
11 mitotic nuclear envelope reassembly GO:0007084 9.43 BANF1 VRK1
12 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.4 IRF3 IRF7
13 viral process GO:0016032 9.36 AZI2 BANF1 EIF2AK2 EPS15 IRF3 IRF7
14 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.33 IRF3 IRF7 TANK
15 type I interferon biosynthetic process GO:0045351 9.32 IRF3 IRF7
16 MDA-5 signaling pathway GO:0039530 9.26 IRF3 IRF7
17 interferon-alpha production GO:0032607 8.96 AZI2 IRF7

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AZI2 BANF1 CYB5R3 EIF2AK2 EIF2S1 EPS15
2 kinase activator activity GO:0019209 8.96 IL2 ITSN1

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....